Navigation Links
Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
Date:7/24/2008

New JIT Enrollment Program Speeds Oncology Patient Accrual

DENVER, July 24 /PRNewswire/ -- Pharmatech, Inc., a Research Management Organization (RMO), has contracted with five leading pharmaceutical companies to provide research and site management services for their clinical trials using the Just-in-Time (JIT) enrollment strategy. The new trials include the following disease indications: follicular Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Metastatic Sarcoma, Chronic Myelogenous Leukemia, and Non-Small Cell Lung Cancer (NSCLC).

Pharmatech will manage the trials using its innovative JIT approach. This streamlined approach was created to increase enrollment in oncology clinical trials. This patient first initiative allows for identification of cancer patients through basic standard of care procedures, so the site opens only if the patient qualifies for the study. Patient enrollment increases because a protocol is rolled out to a large number of qualified Research Network sites with minimal expense of time and capital for both the sites and sponsors.

The new oncology clinical trials are targeted to achieve enrollment of over 500 cancer patients with the participation of approximately 165 Pharmatech Research Network sites. Matthew Wiener, Pharmatech CEO, states that "The recent activity in new business has been a true testament to the acceptance of the Just-In-Time enrollment strategy. Study sponsors and sites have praised the new enrollment methodology, as cancer patients are treated in a more efficient manner and sponsors see their trials completed in a shorter time frame."

About Pharmatech, Inc.:

Pharmatech, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech, please visit http://www.pharmatech.com.

Key Words: Oncology, Clinical Trials, Cancer Patients, CRO, SMO, Lymphoma, Leukemia, Breast Cancer, Lung Cancer, Sarcoma, Just-In-Time


'/>"/>
SOURCE Pharmatech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
2. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
3. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
4. VIRxSYS to Host a Web Conference to Announce Clinical Trial Update
5. New AAHC Toolkit Available to Optimize Clinical Research Administration
6. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
7. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
8. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
9. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
10. BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
11. AFFiRiS: Milestone Reached in Clinical Trial of Alzheimers Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... SPRING, Md. , Dec. 2, 2016 ... new indication for Jardiance (empagliflozin) to reduce the risk ... diabetes mellitus and cardiovascular disease. "Cardiovascular ... with type 2 diabetes mellitus," said Jean-Marc Guettier ... and Endocrinology Products in FDA,s Center for Drug Evaluation ...
(Date:12/2/2016)... , December 2, 2016 ... global cardiac pacemaker market in its upcoming report titled, "Global Market Study ... a Declining CAGR of -1.4% between 2016 and 2024". The ... Mn in 2015 and this is likely to decline ... revenue, the global cardiac pacemaker market is anticipated to ...
(Date:12/2/2016)... , December 2, 2016 According to ... "Global Market Study on Automated Endoscope Reprocessors: Single Basin Automated ... of 8.6% Between 2016 and 2024 " the global automated endoscope reprocessors ... expected to expand at a CAGR of 7.2% during an ... US$ 1,367.6 Mn by 2024. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest ... patients, standing as living proof that attitude and determination can combine into the ... that spike around the holidays. This campaign will offer patients a new-found hope, ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd ... Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to ... , The demand for supplemental training related to pain management has surged ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 ... to create versatile lower third titles with just a few clicks of the mouse," ... 2 includes 30 lower third animations. Choose from various styles with accented animations, rigid ...
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 , ... ... they are winners of $1,000 each from the National Family Partnership and the Drug ... winning families who decorated their homes and the 10 winning schools who decorated their ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... treatment has announced the opening of a new eating disorder treatment center location ... outpatient treatment for adults and adolescents, both males and females ages 10 and ...
Breaking Medicine News(10 mins):